<b>Chemoradiotherapy</b> protocols are a recent development in the management of tumours where preservation of organ function is important. It is now recognized <b>that such combined treatment may produce adverse effects above the accepted dose thresholds for either modality, including increased cardiotoxicity with adriamycin.</b> However, there was a study done for inoperable lung cancer that showed local control and survival was improved by combining radiotherapy with daily low-dose cisplatin. <b>As usual, the risk benefit profile requires consideration.</b> 

The dosages and timing of the chemotherapy agent(s) and the radiation determine the effectiveness of the regimen. Timing between Xray irradiation and chemotherapy dose may be critical.

Hyperthermia in combination with chemotherapy has a strong biological rationale based on thermal enhancement of cytotoxicity and partial circumvention of resistance. Weekly locoregional hyperthermia or whole-body hyperthermia using the Aquatherm apparatus, in combination with chemotherapy is feasible. Some results in patients with metastatic sarcomas were promising.

The formation of a blood supply (angiogenesis) is critical to the growth of solid tumors. Addition of antiangiogenic agents to treatment with cytotoxic therapies might make standard anticancer therapies more powerful.

Interleukin-1 might have a protective effect on normal tissues' response to radiation and chemotherapy damage, while not affecting tumor response to treatment. For some drugs, the protection might be dependent on sequence of administration.

&&url